<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580813</url>
  </required_header>
  <id_info>
    <org_study_id>10-1393</org_study_id>
    <nct_id>NCT01580813</nct_id>
  </id_info>
  <brief_title>Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes</brief_title>
  <acronym>AcT2</acronym>
  <official_title>Effects of Serum Fatty Acid Lowering on Insulin Sensitivity, Cardiovascular Function, And Exercise Capacity in Non-Insulin Dependent Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      People who are overweight or who have type 2 diabetes mellitus (T2DM) have higher levels of&#xD;
      certain fats in their blood. The blood vessels and heart of most of these individuals do not&#xD;
      work normally and people with T2DM also have an impaired ability to perform exercise. The&#xD;
      purpose of this study is to use the free fatty acid lowering drug, acipimox, to temporarily&#xD;
      decrease the level of fat in the bloodstream of people with T2DM and observe the&#xD;
      physiological changes to blood vessel function and exercise capacity and insulin sensitivity.&#xD;
      This will help the investigators to understand ways of improving blood vessel function and&#xD;
      the ability to exercise effectively in people who are overweight or have T2DM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating the Effect of Acipimox on Insulin Sensitivity and Cardiovascular Function</measure>
    <time_frame>2 years</time_frame>
    <description>Test the hypothesis that lowering of endogenous non-essential fatty acids (NEFA) in diabetic adults will improve insulin sensitivity, inflammation, and endothelial and cardiac function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Impact of Acipimox on Exercise Parameters in People with Type 2 Diabetes</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the impact of these effects of NEFA-lowering on exercise parameters, including VO2 kinetics, peak VO2, peak heart rate, peak power output, and peak exercise cardiac function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Acipimox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visi</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acipimox</intervention_name>
    <description>Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.</description>
    <arm_group_label>Acipimox</arm_group_label>
    <other_name>Olbetam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sedentary adults not participating in a regular exercise program (≤ one bout of&#xD;
             scheduled exercise per week)&#xD;
&#xD;
          -  Subjects must have Type 2 Diabetes&#xD;
&#xD;
          -  Subjects must be otherwise healthy&#xD;
&#xD;
          -  Ages of 30-60 years&#xD;
&#xD;
          -  BMI of 25-39 and stable weight for 3 months prior to the start of the study&#xD;
&#xD;
          -  Diabetes controlled by diet +/- insulin secretagogues (sulfonylureas or glinides),&#xD;
             metformin, or glucose absorption blockers (acarbose).&#xD;
&#xD;
          -  Total glycosylated hemoglobin levels (HbA1C) ≤9% (fair control) on current therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any comorbid condition which could limit exercise performance including Chronic&#xD;
             Obstructive Pulmonary Disease (COPD) or asthma&#xD;
&#xD;
          -  Concurrent enrollment in an interventional study.&#xD;
&#xD;
          -  Any tobacco use either current or within the last year&#xD;
&#xD;
          -  Clinically evident distal symmetrical neuropathy, determined by evaluation of symptoms&#xD;
             (numbness, paresthesia) and signs (elicited by vibration, pinprick, light touch, ankle&#xD;
             jerks), will be excluded.&#xD;
&#xD;
          -  Autonomic dysfunction (&gt;20 mm fall in upright BP without a change in heart rate) will&#xD;
             be excluded.&#xD;
&#xD;
          -  Evidence of ischemic heart disease by history or abnormal resting or exercise&#xD;
             electrocardiogram (EKG) (&gt; 1 mm ST segment depression) on screening exercise test.&#xD;
&#xD;
          -  Angina or any other cardiovascular, pulmonary or musculoskeletal symptoms&#xD;
&#xD;
          -  Presence of systolic blood pressure &gt;190 at rest or &gt;250 with exercise or diastolic&#xD;
             pressure &gt;95 at rest or &gt;105 with exercise&#xD;
&#xD;
          -  Proteinuria (urine protein &gt;200 mg/dl) or a creatinine &gt; 2 mg/dl, suggestive of severe&#xD;
             renal disease&#xD;
&#xD;
          -  Proliferative retinopathy&#xD;
&#xD;
          -  Insulin, incretin, or glitazone treatment&#xD;
&#xD;
          -  Niacin treatment&#xD;
&#xD;
          -  History of peptic ulcers&#xD;
&#xD;
          -  A history of hereditary angioedema&#xD;
&#xD;
          -  C1 esterase deficiency&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Use of fibrate drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Schauer, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>exercise</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>heart</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 7, 2021</submitted>
    <returned>November 4, 2021</returned>
    <submitted>November 5, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

